Integragen (France) Executives
| ALINT Stock | EUR 0.74 0.02 2.78% |
Integragen employs about 52 people. The company is managed by 18 executives with a total tenure of roughly 115 years, averaging almost 6.0 years of service per executive, having 2.89 employees per reported executive. Discussion of Integragen's management performance can provide insight into the enterprise performance.
| Larry Yost CEO Chief Executive Officer - Integragen Inc |
| Bernard Courtieu Chairman Chairman of the Board, Chief Executive Officer |
Integragen |
Integragen Management Team Effectiveness
The company has return on total asset (ROA) of 0.0149 % which means that it generated a profit of $0.0149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Integragen's management efficiency ratios could be used to measure how well Integragen manages its routine affairs as well as how well it operates its assets and liabilities.Integragen Workforce Comparison
Integragen is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 255. Integragen totals roughly 52.0 in number of employees claiming about 20% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02. Integragen Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Integragen Price Series Summation is a cross summation of Integragen price series and its benchmark/peer.
Integragen Notable Stakeholders
An Integragen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Integragen often face trade-offs trying to please all of them. Integragen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Integragen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Larry Yost | Chief Executive Officer - Integragen Inc | Profile | |
| Bernard Courtieu | Chairman of the Board, Chief Executive Officer | Profile | |
| Francois Liebaert | Vice President - Research & Development and Medical Affairs | Profile | |
| Emmanuel Martin | Director Sales & Marketing for the Services Business Unit | Profile | |
| Gerald Wagner | Director | Profile | |
| Laurence Lamotte | Director of Administration and Finance | Profile | |
| Benoit Adelus | Director | Profile | |
| Philippe Boucheron | Director, representing CDC Entreprises | Profile | |
| Francis Rousseau | Director of Genomics | Profile | |
| Chantal Parpex | Director, representing CDC Innovation | Profile | |
| Louis Nisbet | Director, representing Kurma Life Sciences Partners | Profile | |
| Cyril Harfouche | Director | Profile | |
| MBA DVM | CEO Director | Profile | |
| Joerg Leenings | Head Centre | Profile | |
| JeanPol Detiffe | Chief Director | Profile | |
| Brengre Gnin | Research Academics | Profile | |
| Anne Philippi | CoFounder Epidemiology | Profile | |
| Pierre Flamant | Adm Director | Profile |
About Integragen Management Performance
The success or failure of an entity such as Integragen often depends on how effective the management is. Integragen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Integragen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Integragen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people.
Integragen Workforce Analysis
Traditionally, organizations such as Integragen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Integragen within its industry.Integragen Manpower Efficiency
Return on Integragen Manpower
| Revenue Per Employee | 217.8K | |
| Revenue Per Executive | 629.1K | |
| Net Income Per Employee | 288 | |
| Net Income Per Executive | 833 | |
| Working Capital Per Employee | 38.5K | |
| Working Capital Per Executive | 111.1K |
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.